(c) 2023 PillSync.com

buspirone hydrochloride tablet

INDICATIONS AND USAGE Buspirone hydrochloride tablets are indicated for the management of anxiety disorder or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association's Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling "on edge," irritability, impatience. The above symptoms would not be due to another mental disorder, such as a depressive disorder or schizophrenia. However, mild depressive symptoms are common in GAD. The effectiveness of buspirone hydrochloride tablets in long-term use, that is, for more than 3 to 4 weeks, has not been demonstrated in controlled trials. There is no body of evidence available that systematically addresses the appropriate duration of treatment for GAD. However, in a study of long- term use, 264 patients were treated with buspirone hydrochloride tablets for 1 year without ill effect. Therefore, the physician who elects to use buspirone hydrochloride tablets for extended periods should periodically reassess the usefulness of the drug for the individual patient.

Inventia Healthcare Private Limited


2 years ago OVAL WHITE 098 buspirone hydrochloride tablet

OVAL WHITE 098

HOW SUPPLIED Buspirone Hydrochloride Tablets, USP 5 mg are available as white to off white, flat faced, capsule shaped tablet, functionally-scored on one side and debossed with "098" on other side, packaged in bottles of 60 tablets (NDC 49252-098-11),100 tablets (NDC 49252-098-13), 500 tablets (NDC 49252-098-17) and 1000 tablets (NDC 49252-098-18) and carton of 100 (10 x 10) unit-dose tablets (NDC 49252-098-57). Buspirone Hydrochloride Tablets, USP 7.5 mg are available as white to off white, flat faced, capsule shaped tablet, scored on one side and debossed with "107" on other side, packaged in bottles of 60 tablets (NDC 49252-107-11),100 tablets (NDC 49252-107-13), 500 tablets (NDC 49252-107-17) and 1000 tablets (NDC 49252-107-18) and carton of 100 (10 x 10) unit-dose tablets (NDC 49252-107-57). Buspirone Hydrochloride Tablets, USP 10 mg are available as white to off white, flat faced, capsule shaped tablet, functionally-scored on one side and debossed with "099" on other side, packaged in bottles of 60 tablets (NDC 49252-099-11),100 tablets (NDC 49252-099-13), 500 tablets (NDC 49252-099-17) and 1000 tablets (NDC 49252-099-18) and carton of 100 (10 x 10) unit-dose tablets (NDC 49252-099-57) Buspirone Hydrochloride Tablets, USP 30 mg are available as white to off white, flat faced, capsule shaped, functionally-scored tablet that can be bisected or trisected, debossed with “1” and “00” on bisect segments, and debossed "5" on each trisect segment, packaged in bottles of 60 tablets (NDC 49252-100-11),100 tablets (NDC 49252-100-13), 500 tablets (NDC 49252-100-17) and 1000 tablets (NDC 49252-100-18) and carton of 100 (10 x 10) unit-dose tablets (NDC 49252-100-57). Buspirone Hydrochloride Tablets, USP 30 mg are available as white to off white, flat faced, capsule shaped, functionally-scored tablet that can be bisected or trisected, debossed with “1” and “01” on bisect segments, and debossed "10" on each trisect segment, packaged in bottles of 60 tablets (NDC 49252-101-11),100 tablets (NDC 49252-101-13), 500 tablets (NDC 49252-101-17) and 1000 tablets (NDC 49252-101-18) and carton of 100 (10 x 10) unit-dose tablets (NDC 49252-101-57). Store at 20 o to 25 o C (68 o to 77 o F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container (USP).

More pills like OVAL 098

Related Pills

buspirone hydrochloride 7.5 MG Oral Tablet

inventia healthcare private limited

buspirone hydrochloride 10 MG Oral Tablet

inventia healthcare private limited

buspirone hydrochloride 15 MG Oral Tablet

inventia healthcare private limited

buspirone hydrochloride tablet

inventia healthcare private limited












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site